Skip to main content
TipRanks
Go Ultimate75% OFF

Oncolys BioPharma, Inc. (4588) Ratios

1 Followers

Oncolys BioPharma, Inc. Ratios

JP:4588's free cash flow for Q4 2025 was ¥0.00. For the 2025 fiscal year, JP:4588's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio9.5512.285.178.119.76
Quick Ratio9.5412.265.158.049.73
Cash Ratio7.819.553.404.567.46
Solvency Ratio-3.70-3.77-3.42-2.33-2.31
Operating Cash Flow Ratio-4.12-8.00-3.53-5.34-4.05
Short-Term Operating Cash Flow Coverage-7.97-15.81-10.46-7.54-7.29
Net Current Asset Value¥ 3.94B¥ 2.65B¥ 1.39B¥ 2.12B¥ 3.50B
Leverage Ratios
Debt-to-Assets Ratio0.070.100.150.150.12
Debt-to-Equity Ratio0.080.120.210.180.14
Debt-to-Capital Ratio0.070.110.180.150.12
Long-Term Debt-to-Capital Ratio0.020.060.100.070.07
Financial Leverage Ratio1.141.161.381.231.19
Debt Service Coverage Ratio-8.25-12.69-14.71-4.94-6.60
Interest Coverage Ratio-386.72-365.76-535.81-305.32-348.90
Debt to Market Cap0.010.030.030.040.06
Interest Debt Per Share12.6415.0817.9122.9530.01
Net Debt to EBITDA1.641.250.500.941.69
Profitability Margins
Gross Profit Margin99.15%100.00%48.55%34.67%30.94%
EBIT Margin-7177.12%-5341.63%-3064.78%-116.99%-250.20%
EBITDA Margin-7176.27%-5339.03%-3061.15%-116.90%-249.19%
Operating Profit Margin-7090.55%-5357.52%-3061.62%-123.39%-226.39%
Pretax Profit Margin-7195.46%-5356.28%-3070.49%-117.40%-250.85%
Net Profit Margin-7209.59%-5368.27%-3075.14%-117.70%-251.43%
Continuous Operations Profit Margin-7209.58%-5368.27%-3075.14%-117.70%-251.43%
Net Income Per EBT100.20%100.22%100.15%100.26%100.23%
EBT Per EBIT101.48%99.98%100.29%95.14%110.80%
Return on Assets (ROA)-45.17%-52.67%-95.00%-43.34%-37.64%
Return on Equity (ROE)-51.45%-61.22%-131.50%-53.21%-44.95%
Return on Capital Employed (ROCE)-49.55%-57.07%-116.12%-51.71%-37.67%
Return on Invested Capital (ROIC)-46.76%-54.51%-107.38%-47.04%-35.45%
Return on Tangible Assets-45.17%-52.67%-95.00%-43.34%-37.64%
Earnings Yield-5.78%-14.90%-19.21%-12.58%-18.09%
Efficiency Ratios
Receivables Turnover0.080.310.623.071.82
Payables Turnover0.000.000.1710.484.18
Inventory Turnover0.060.186.0726.3038.07
Fixed Asset Turnover0.000.000.0046.1630.28
Asset Turnover0.010.010.030.370.15
Working Capital Turnover Ratio0.010.010.030.320.22
Cash Conversion Cycle10681.943241.39-1526.7698.10122.24
Days of Sales Outstanding4775.571191.12589.12119.05200.05
Days of Inventory Outstanding5906.362050.2760.1213.889.59
Days of Payables Outstanding0.000.002176.0034.8387.40
Operating Cycle10681.943241.39649.24132.93209.64
Cash Flow Ratios
Operating Cash Flow Per Share-75.44-92.53-75.12-99.10-102.97
Free Cash Flow Per Share-75.56-92.69-75.44-99.18-103.06
Dividend Paid and CapEx Coverage Ratio-643.95-574.05-235.13-1264.46-1212.13
Capital Expenditure Coverage Ratio-643.95-574.05-235.13-1264.46-1212.13
Operating Cash Flow Coverage Ratio-6.06-6.22-4.24-4.36-3.46
Operating Cash Flow to Sales Ratio-67.99-64.37-21.21-1.76-2.71
Free Cash Flow Yield-5.46%-17.89%-13.30%-18.82%-19.52%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-17.30-6.71-5.21-7.95-5.53
Price-to-Sales (P/S) Ratio1247.26360.33160.089.3513.90
Price-to-Book (P/B) Ratio8.904.116.854.232.49
Price-to-Free Cash Flow (P/FCF) Ratio-18.32-5.59-7.52-5.31-5.12
Price-to-Operating Cash Flow Ratio-18.34-5.60-7.55-5.32-5.13
Price-to-Earnings Growth (PEG) Ratio-4.720.23-0.080.260.16
Enterprise Value Multiple-15.74-5.50-4.73-7.06-3.89
Enterprise Value32.25B9.22B9.12B8.06B6.23B
EV to EBITDA-15.74-5.50-4.73-7.06-3.89
EV to Sales1129.74293.85144.658.269.69
EV to Free Cash Flow-16.59-4.56-6.79-4.69-3.57
EV to Operating Cash Flow-16.62-4.57-6.82-4.69-3.57
Tangible Book Value Per Share155.49126.0782.83124.62212.47
Shareholders’ Equity Per Share155.49126.0782.83124.62212.47
Tax and Other Ratios
Effective Tax Rate-0.00-0.00-0.00-0.00-0.00
Revenue Per Share1.111.443.5456.3437.98
Net Income Per Share-80.00-77.17-108.92-66.31-95.50
Tax Burden1.001.001.001.001.00
Interest Burden1.001.001.001.001.00
Research & Development to Revenue51.5134.7021.450.971.28
SG&A to Revenue20.3954.770.000.000.00
Stock-Based Compensation to Revenue0.000.620.160.060.33
Income Quality0.941.200.691.501.08

Currency in JPY